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Introduction
CV9104 is a novel mRNA-based therapeutic vaccine for
prostate cancer encoding the prostate cancer-associated
antigens PSA, PSMA, PSCA, STEAP, PAP and MUC1
by engineered mRNA molecules optimized for protein
expression and immunostimulation (RNActive®).
CV9103, an mRNA-based vaccine against 4 of these
antigens was previously shown to be safe and immuno-
genic in a pPhase I/IIA trial. Immune responses against
multiple antigens were associated with improved survi-
val in patients with mCRPC.
Design and methods
Safety and immunogenicity of first human exposure to
CV9104 was investigated in the Phase I part. In the
Phase II part, chemotherapy-naïve patients with a- or
minimally symptomatic mCRPC were randomized to
CV9104 or placebo. Primary endpoint is overall survival.
Secondary endpoints include progression free survival,
quality of life and immunogenicity among others. Upon
disease or symptom progression blinded treatment is
continued in combination with the subsequent systemic
cancer treatment until second progression. Blood sam-
ples for immune monitoring and other biomarkers were
taken at baseline, week 6 (1 week post fourth vaccina-
tion) and week 24 (6 weeks post ninth vaccination).
Cellular and humoral immune responses against all vac-
cine antigens were analyzed by intracellular cytokine
staining and IgM and IgG ELISA, respectively. Blood
leukocyte phenotyping was performed by flow cytome-
try. Transcriptome analyses in whole blood were per-
formed and serum samples are currently analyzed for
miRNAs.
Results
Seven patients were enrolled in the Phase I part. Six of
these patients were evaluable for immune responses.
The independent data monitoring board recommended
continuation into Phase II since nature and severity of
adverse events were favorable and in line with previous
results from CV9103 Recruitment of the Phase II part
was finished in 12/2013 with 197 patients randomized.
The trial is ongoing.
5 of 6 patients of the Phase I part exhibited antigen-spe-
cific immune responses post vaccination. All CV9104 anti-
gens were immunogenic. Multiple immune responses
against ≥2 antigens were observed in 2 patients. In addi-
tion, phenotypic changes in CD4+ and CD8+ T cells con-
sistent with an effector phenotype were observed.
Conclusion
Results from the Phase I part suggest that the self-
adjuvanted mRNA vaccine CV9104 constitutes a well-
tolerated approach to induce antigen-specific cellular5Curevac GmbH, Frankfurt, Germany
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